| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Fernández-Rubio, Beatriz |
| dc.contributor.author | Luque-Marquez, Rafael |
| dc.contributor.author | López-Cortés, Luis Eduardo |
| dc.contributor.author | Luque-Pardos, Sonia |
| dc.contributor.author | Fernandez-Polo, Aurora |
| dc.contributor.author | Herrera Hidalgo, Laura |
| dc.contributor.author | de Alarcón González, Arístides |
| dc.date.accessioned | 2024-02-27T08:45:34Z |
| dc.date.available | 2024-02-27T08:45:34Z |
| dc.date.issued | 2023-11-30 |
| dc.identifier.citation | Fernández-Rubio B, Herrera-Hidalgo L, de Alarcón A, Luque-Márquez R, López-Cortés LE, Luque S, et al. Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy. Pharmaceutics. 2023 Nov 30;15(12):2705. |
| dc.identifier.issn | 1999-4923 |
| dc.identifier.uri | https://hdl.handle.net/11351/11125 |
| dc.description | Pseudomonas aeruginosa; Beta lactams; Multidrug-resistant bacteria |
| dc.description.abstract | Outpatient parenteral antimicrobial therapy (OPAT) is a useful treatment strategy against Pseudomonas aeruginosa and other multidrug-resistant bacteria. However, it is hindered by the lack of stability data for the administration of antibiotics under OPAT conditions. Our objective was to investigate the stability of nine antipseudomonal and broad-spectrum beta lactam antibiotics (aztreonam, cefepime, cefiderocol, ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, meropenem, meropenem/vaborbactam, and piperacillin/tazobactam) to allow the spread of OPAT programs. All the antibiotics were diluted in 500 mL 0.9% sodium chloride and stored at 4, 25, 32, and 37 °C for 72 h in two different devices (infusion bags and elastomeric pumps). The solutions were considered stable if the color, clearness, and pH remained unchanged and if the percentage of intact drug was ≥90%. All the antimicrobials remained stable 72 h under refrigerated conditions and at least 30 h at 25 °C. At 32 °C, all the antibiotics except for meropenem and meropenem/vaborbactam remained stable for 24 h or more. At 37 °C, only aztreonam, piperacillin/tazobactam, cefepime, cefiderocol, and ceftolozane/tazobactam were stable for at least 24 h. The stability results were the same in the two devices tested. All the antibiotics studied are actual alternatives for the treatment of antipseudomonal or multidrug-resistant infections in OPAT programs, although the temperature of the devices is crucial to ensure antibiotic stability. |
| dc.language.iso | eng |
| dc.publisher | MDPI |
| dc.relation.ispartofseries | Pharmaceutics;15(12) |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Pseudomones aeruginosa |
| dc.subject | Malalties bacterianes - Tractament |
| dc.subject | Microorganismes - Resistència als medicaments |
| dc.subject.mesh | Anti-Bacterial Agents |
| dc.subject.mesh | Drug Resistance, Multiple |
| dc.subject.mesh | Pseudomonas Infections |
| dc.title | Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.3390/pharmaceutics15122705 |
| dc.subject.decs | antibacterianos |
| dc.subject.decs | resistencia múltiple a medicamentos |
| dc.subject.decs | infecciones por Pseudomonas |
| dc.relation.publishversion | https://doi.org/10.3390/pharmaceutics15122705 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Fernández-Rubio B] Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain. [Herrera-Hidalgo L] Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain. Unidad de Gestión Clínica de Enfermedades Infecciosas, Microbiología y Parasitologia, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain. Centro de Investigación en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. [de Alarcón A, Luque-Márquez R] Unidad de Gestión Clínica de Enfermedades Infecciosas, Microbiología y Parasitologia, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain. Centro de Investigación en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. [López-Cortés LE] Centro de Investigación en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Infectious Diseases and Microbiology Clinical Unit, University Hospital Virgen Macarena/Department of Medicine, School of Medicine, University of Sevilla/Biomedicine Institute of Sevilla (IBiS)/CSIC, Seville, Spain. [Luque S] Centro de Investigación en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Pharmacy Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain. Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain. [Fernández-Polo A] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain |
| dc.identifier.pmid | 38140046 |
| dc.identifier.wos | 001132585500001 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |